logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
JANX
Janux Therapeutics, Inc.
14.66
2 x 11.09
2 x 18.89
bid
ask
-
0.70
4.56%
2 @ 04:00 PM
14.63 -0.03 (0.20%)
Ytd6.23%
1y-36.86%
14.61
day range
15.62
12.12
52 week range
35.34
Open15.48Prev Close15.36Low14.61High15.62Mkt Cap894.03M
Vol1.61MAvg Vol1.11MEPS-1.84P/EN/AForward P/E-9.91
Beta2.82Short Ratio6.19Inst. Own110.14%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg14.35200-d Avg17.681yr Est76.71

JANX News

benzinga.com
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy r
benzinga.com
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight
benzinga.com
Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and

benzinga.com
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t
benzinga.com
Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28

Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowe

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move
benzinga.com
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move

Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs d
benzinga.com
Janux Therapeutics Discontinues JANX008 Cancer Program To Prioritize Higher-Potential Pipeline Oppor

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company
benzinga.com
Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14

Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Unde
benzinga.com
Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
benzinga.com
UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15

UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers

benzinga.com
Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Brist

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
benzinga.com
Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100

Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overwei
benzinga.com
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $68

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t
benzinga.com
Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analy

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
benzinga.com
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol My

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company
benzinga.com
Clear Street Downgrades Janux Therapeutics to Hold, Lowers Price Target to $12

Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold

benzinga.com
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $30

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight
benzinga.com
Janux Therapeutics Provides Phase 1 Update on EGFR-Targeted JANX008; The Program Has Initiated Expan

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
benzinga.com
Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29

Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lo

Gold Down Over 1%; Signet Shares Fall After Q3 Results
benzinga.com
Gold Down Over 1%; Signet Shares Fall After Q3 Results
benzinga.com
Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38

Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers th

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Janux Therapeutics Stock Hits 52-Week Low After Trial Update
benzinga.com
Janux Therapeutics Stock Hits 52-Week Low After Trial Update

JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy a

Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings
benzinga.com
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings

Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
Clear Street Maintains Buy on Janux Therapeutics, Lowers Price Target to $32

Clear Street analyst Kaveri Pohlman maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and low
benzinga.com
B of A Securities Maintains Buy on Janux Therapeutics, Lowers Price Target to $49

B of A Securities analyst Geoff Meacham maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Marke
benzinga.com
Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $150

Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overwei

Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Lowers Price Target to $45

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX)
benzinga.com
Janux Therapeutics Data From Phase 1 Clinical Study Of JANX007 Demonstrates High Prostate-Specific A

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developi

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX
benzinga.com
Janux Therapeutics CEO To Provide Update On JANX007 Primarily Focused On Phase 1a Dose Escalation Da

The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ETJanux Therapeutics, Inc.
benzinga.com
Wolfe Research Initiates Coverage On Janux Therapeutics with Peer Perform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a
benzinga.com
Barclays Maintains Overweight on Janux Therapeutics, Raises Price Target to $48

Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and ra
benzinga.com
Janux Therapeutics Q3 EPS $(0.39) Beats $(0.60) Estimate, Sales $10.000M Beat $2.929M Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.39) per share which beat the analy
benzinga.com
Barclays Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of

Barclays analyst Etzer Darout initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overw
benzinga.com
Truist Securities Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target o

Truist Securities analyst Asthika Goonewardene initiates coverage on Janux Therapeutics (NASDAQ:J
benzinga.com
Stifel Reinstates Buy on Janux Therapeutics, Announces $45 Price Target

Stifel analyst Bradley Canino reinstates Janux Therapeutics (NASDAQ:JANX) with a Buy and announce
benzinga.com
Guggenheim Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $72

Guggenheim analyst Brad Canino initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy

benzinga.com
Piper Sandler Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Targe

Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ:JANX) with

benzinga.com
Janux Therapeutics Announces The Dosing Of The First Patient In Its TRACTr Collaboration With Merck;

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
benzinga.com
Janux Therapeutics Showcases Advancements In TRACTr, TRACIr, And ARM Platforms Ahead Of 2026 Trials

PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide C
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
benzinga.com
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday